China Medicine Corp. (CHME)
China Medicine Corp. operates in the Medical - Pharmaceuticals industry of the Healthcare sector, headquartered in Guangzhou, GD, CN. The stock last traded at $0.02, up 0.00% on the session, giving a market capitalisation of $474,241. On trailing twelve-month figures it carries a trailing P/E of 0.18, a net margin of 2.7%. Its beta of -8.66 implies it has historically moved less than the broad market.
China Medicine Corporation produces and distributes prescription and over the counter drugs, traditional Chinese medicine products, herbs and dietary-supplements, medical devices, and medical formulations in China. The company offers various products for applications, including oncology, high blood pressure, and removal of toxins from food and animal feeds. It provides products that treat stagnation of the heart blood, obstruction of qi in the chest, cardiodynia, headache, and dysmenorrhea; upper respiratory tract infection, acute faucitis, acute tonsillitis, acute gastroenteritis, etc.; acute and chronic hepatitis, deferment hepatitis, cholecystitis, etc.; irregular menstruation, dysmenorrhea, and amenorrhea; anemia and deficiency of vital energy; palpitation, dizziness, and fatigue; and cerebral arteriosclerosis and ischemic stroke. The company distributes its products through a sales network in China. The company was formerly known as Lounsberry Holdings III, Inc. and changed its name to China Medicine Corporation in May 2006. China Medicine Corporation was founded in 2005 and is based in Guangzhou, China.
China Medicine Corp. is most often compared with the following Healthcare names: